Gene expression profiles as predictors of poor outcomes in stage ii colorectal cancer: A systematic review and meta-analysis

Clinical Colorectal Cancer

Volumn 8, Issue 4, 2009, Pages 207-214

  Lu, An Ting ^a   Salpeter, Shelley R ^a,b   Reeve, Anthony E ^c   Eschrich, Steven ^d   Johnston, Patrick G ^e   Barrier, Alain J ^f   Bertucci, Francois ^g   Buckley, Nicholas S ^h   Salpeter, Edwin E ⁱ   Lin, Albert Y ^a,b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF OTAGO   (New Zealand)

^d H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

^e QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^f UNIVERSITÉ DE MONTRÉAL   (Canada)

^g INSTITUT PAOLI CALMETTES   (France)

^h CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

ⁱ Department of Obstetrics Gynecology   (United States)

Author keywords

DNA microarray; Gene signature; Likelihood ratio; Prognosis prediction

Indexed keywords

ACCURACY; ARTICLE; CANCER RECURRENCE; CLINICAL DECISION MAKING; COLORECTAL CANCER; CONFIDENCE INTERVAL; DNA MICROARRAY; GENE EXPRESSION PROFILING; HUMAN; OUTCOME ASSESSMENT; PREDICTIVE VALIDITY; PREDICTOR VARIABLE; PROGNOSIS; RISK; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; SYSTEMATIC REVIEW;

ANTINEOPLASTIC AGENTS; COLORECTAL NEOPLASMS; DNA, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 70350148373     PISSN: 15330028     EISSN: None     Source Type: Journal    
DOI: 10.3816/CCC.2009.n.035     Document Type: Article

References (70)

1. Jemal A, Siegel R, Ward E, et al. Cancer Statistics, 2008. CA Cancer J Clin 2008; 58:71-96.
2. Greenlee RT, Murray T, Bolden S, et al. Cancer statistics, 2000. CA Cancer J Clin 2000; 50:7-33.
3. Saltz M, Leonard B, Kelsen M, et al. Adjuvant treatment of colorectal cancer. Annu Rev Med 1997; 48:191-202.
4. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322:352-358
5. Wolmark N, Rockette H, Mamounas E, et al. Clinical trial to assess the relative efficacy of fluorouracil and leucovorin, fluorouracil and levamisole, and fluorouracil, leucovorin, and levamisole in patients with Dukes' B and C carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project C-04. J Clin Oncol 1999; 17:3553-3559 (Pubitemid 29517927)
6. Moertel CG, Fleming TR, Macdonald JS, et al. Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 1995; 122:321-326
7. Benson AB, III, Schrag D, Somerfield MR, et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22:3408-3419
8. Figueredo A, Charette ML, Maroun J, et al. Adjuvant therapy for stage II colon cancer: A systematic review from the Cancer Care Ontario Program in Evidence- Based Care's Gastrointestinal Cancer Disease Site Group. J Clin Oncol 2004; 22:3395-3407
9. QUASAR Collaborative Group. Adjuvant chemotherapy versus observation in patients with colorectal cancer: A randomised study. Lancet 2007; 370:2020-2029
10. André T, Sargent D, Tabernero J, et al. Current issues in adjuvant treatment of stage II colon cancer. Ann Surg Oncol 2006; 13:887-898
11. Johnston PG. Stage II colorectal cancer: To treat or not to treat. Oncologist 2005; 10:332-334
12. Quackenbush J. Microarray analysis and tumor classification. N Engl J Med 2006; 354:2463-2472
13. van 't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature 2002; 415:530-6.
14. van de Vijver MJ, He YD, van 't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002; 347:1999-2009.
15. Sun Z, Wigle DA, Yang P. Non-overlapping and non-cell-type-specific gene expression signatures predict lung cancer survival. J Clin Oncol 2008; 26:877-883
16. Beer DG, Kardia SL, Huang C-C, et al. Gene-expression profiles predict survival of patients with lung adenocarcinoma. Nat Med 2002; 8:816-824
17. Glinsky GV, Glinskii AB, Stephenson AJ, et al. Gene expression profiling predicts clinical outcome of prostate cancer. J Clin Invest 2004; 113:913-923
18. Lapointe J, Li C, Higgins JP, et al. Gene expression profiling identifies clinically relevant subtypes of prostate cancer. Proc Natl Acad Sci USA 2004; 101:811-816
19. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004; 350:1828-1837
20. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:1937-1947
21. Arango D, Laiho P, Kokko A, et al. Gene-expression profiling predicts recurrence in Dukes' C colorectal cancer. Gastroenterology 2005; 129:874-884
22. Barrier A, Boelle P, Brault D, et al. Stage III colon cancer prognosis prediction by gene expression profiling. J Clin Oncol 2007; 25(suppl):587s (Abstract 10590).
23. Wang Y, Jatkoe T, Zhang Y, et al. Gene expression profiles and molecular markers to predict recurrence of Dukes' B colon cancer. J Clin Oncol 2004; 22:1564-1571
24. Barrier A, Boelle P-Y, Lemoine A, et al. Gene expression profiling of nonneoplastic mucosa may predict clinical outcome of colon cancer patients. Dis Colon Rectum 2005; 48:2238-2248
25. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. JAMA 2000; 283:2008-2012
26. Lyman GH, Kuderer NM. Gene expression profile assays as predictors of recurrence- free survival in early-stage breast cancer: a metaanalysis. Clin Breast Cancer 2006; 7:372-379
27. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 1959; 22:719-748
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986; 7:177-188
29. Altman DG, Bland JM. Statistics Notes: Interaction revisited: the difference between two estimates. BMJ 2003; 326:219.
30. Barrier A, Roser F, Boelle P-Y, et al. Prognosis of stage II colon cancer by nonneoplastic mucosa gene expression profiling. Oncogene 2007; 26:2642-2648
31. Bertucci F, Salas S, Eysteries S, et al. Gene expression profiling of colon cancer by DNA microarrays and correlation with histoclinical parameters. Oncogene 2004; 23:1377-1391
32. Eschrich S, Yang I, Bloom G, et al. Molecular staging for survival prediction of colorectal cancer patients. J Clin Oncol 2005; 23:3526-3535
33. Johnston PG, Mulligan K, Kay E, et al. A genetic signature of relapse in stage II colorectal cancer derived from formalin fixed paraffin embedded tissue (FFPE) tissue using a unique disease specific colorectal array. J Clin Oncol 2006; 24(suppl):150s (Abstract 3519).
34. Lin Y-H, Friederichs J, Black MA, et al. Multiple gene expression classifiers from different array platforms predict poor prognosis of colorectal cancer. Clin Cancer Res 2007; 13:498-507.
35. Dudoit S, Van der Laan MJ. Asymptotics of cross-validiation risk estimation in estimator selection and performance assessment. Statist Methodol 2005; 2:131-154
36. Jaeschke R, Guyatt G, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. A. Are the results of the study valid? Evidence-Based Medicine Working Group. JAMA 1994; 271:389-391
37. Jaeschke R, Guyatt GH, Sackett DL. Users' guides to the medical literature. III. How to use an article about a diagnostic test. B. What are the results and will they help me in caring for my patients? The Evidence-Based Medicine Working Group. JAMA 1994; 271:703-707 (Pubitemid 24061707)
38. D'Amico TA. Molecular biologic staging of lung cancer. Annals Thoracic Surg 2008; 85:S737-42.
39. Reddy GK, Balk SP. Clinical utility of microarray-derived genetic signatures in predicting outcomes in prostate cancer. Clin Genitourin Cancer 2006; 5:187-189
40. Leich L, Hartmann L, Burek C, et al. Diagnostic and prognostic significance of gene expression profiling in lymphomas. APMIS 2007; 115:1135-1146
41. Marchionni L, Wilson RF, Wolff AC, et al. Systematic review: Gene expression profiling assays in early-stage breast cancer. Ann Intern Med 2008; 148:358-369
42. Cardoso F, Van't Veer L, Rutgers E, et al. Clinical application of the 70-gene profile: The MINDACT Trial. J Clin Oncol 2008; 26:729-735
43. Sparano JA, Paik S. Development of the 21-gene assay and its application in clini- cal practice and clinical trials. J Clin Oncol 2008; 26:721-728
44. Johnston PG. Of what value genomics in colorectal cancer? Opportunities and challenges. J Clin Oncol 2004; 22:1538-1539
45. Cardoso J, Boer J, Morreau H, et al. Expression and genomic profiling of colorectal cancer. Biochim Biophys Acta 2007; 1775:103-137
46. Ioannidis JP, Lau J. Pooling research results: benefits and limitations of metaanalysis. Jt Comm J Qual Improv 1999; 25:462-469
47. Ein-Dor L, Kela I, Getz G, et al. Outcome signature genes in breast cancer: Is there a unique set? Bioinformatics 2005; 21:171-178
48. King HC, Sinha AA. Gene expression profile analysis by DNA microarrays: promise and pitfalls. JAMA 2001; 286:2280-2288
49. Lin DW, Coleman IM, Hawley S, et al. Influence of surgical manipulation on prostate gene expression: Implications for molecular correlates of treatment effects and disease prognosis. J Clin Oncol 2006; 24:3763-3770
50. Ntzani EE, Ioannidis JP. Predictive ability of DNA microarrays for cancer outcomes and correlates: An empirical assessment. Lancet 2003; 362:1439-1444
51. Massague J. Sorting out breast-cancer gene signatures. N Engl J Med 2007; 356:294-297
52. Simon R, Radmacher MD, Dobbin K, et al. Pitfalls in the use of DNA microarray data for diagnostic and prognostic classification. J Natl Cancer Inst 2003; 95:14-18 (Pubitemid 36124291)
53. Al-Mulla F, Behbehani AI, Bitar MS, et al. Genetic profiling of stage I and II colorectal cancer may predict metastatic relapse. Mod Pathol 2006; 19:648-658
54. Bandres E, Malumbres R, Cubedo E, et al. A gene signature of 8 genes could identify the risk of recurrence and progression in Dukes' B colon cancer patients. Oncol Rep 2007; 17:1089-1094
55. Capella Munar G, Van Laar R, Moreno Aguado V, et al. Prognosis prediction of stage II colon cancer by gene expression profiling. Ann Oncol 2007; 18:vii22-3.
56. Chowdary D, Lathrop J, Skelton J, et al. Prognostic gene expression signatures can be measured in tissues collected in RNAlater preservative. J Mol Diagn 2006; 8:31-39
57. Croner RS, Peters A, Brueckl WM, et al. Microarray versus conventional prediction of lymph node metastasis in colorectal carcinoma. Cancer 2005; 104:395-404.
58. Kim M-Y, Yim S-H, Kwon M-S, et al. Recurrent genomic alterations with impact on survival in colorectal cancer identified by genome-wide array comparative genomic hybridization. Gastroenterology 2006; 131:1913-1924
59. O'Connell MJ, Paik S, Yothers G, et al. Relationship between tumor gene expression and recurrence in stage II/III colon cancer: Quantitative RT-PCR assay of 757 genes in fixed paraffin-embedded (FPE) tissue. J Clin Oncol 2006; 24(suppl):150s (Abstract 3518).
60. Vendrell E, Ribas M, Valls J, et al. Genomic and transcriptomic prognostic factors in R0 Dukes B and C colorectal cancer patients. Int J Oncol 2007; 30:1099-1107
61. Watanabe T, Kobunai T, Toda E, et al. Gene expression signature and the prediction of ulcerative colitis-associated colorectal cancer by DNA microarray. Clin Cancer Res 2007; 13:415-420
62. Cascinu S, Zaniboni A, Scartozzi M, et al. Molecular biology for stage II colorectal cancer: The jury is still out. J Clin Oncol 2007; 25:2861.
63. Barrier A, Boelle P-Y, Houry S, et al. In Reply. J Clin Oncol 2007; 25:2862-2863
64. Simon R. Roadmap for developing and validating therapeutically relevant genomic classifiers. J Clin Oncol 2005; 23:7332-7341
65. Ein-Dor L, Zuk O, Domany E. Thousands of samples are needed to generate a robust gene list for predicting outcome in cancer. Proc Natl Acad Sci USA 2006; 103:5923-5928
66. Fan C, Oh DS, Wessels L, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355:560-569
67. Barrier A, Boelle P-Y, Roser F, et al. Stage II colon cancer prognosis prediction by tumor gene expression profiling. J Clin Oncol 2006; 24:4685-4691
68. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat Rev Genet 2007; 8:341-52.
69. Son CG, Bilke S, Davis S, et al. Database of mRNA gene expression profiles of multiple human organs. Genome Res 2005; 15:443-450
70. Minna JD, Girard L, Xie Y. Tumor mRNA expression profiles predict responses to chemotherapy. J Clin Oncol 2007; 25:4329-4336